Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38"

Robert S. Rosenstein, David Parra

Research output: Contribution to journal › Article

Original languageEnglish
JournalCirculation
Volume119
Issue number25
DOIs
StatePublished - Jun 30 2009

Fingerprint

Piperazines
Coronary Thrombosis
Thiophenes
Platelet Aggregation Inhibitors
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Oral Administration
Diabetes Mellitus
Blood Platelets
Myocardial Infarction
Therapeutics
Prasugrel Hydrochloride

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel : Thrombolysis in myocardial infarction 38". / Rosenstein, Robert S.; Parra, David.

In: Circulation, Vol. 119, No. 25, 30.06.2009.

Research output: Contribution to journal › Article

Rosenstein, RS & Parra, D 2009, 'Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38"', Circulation, vol. 119, no. 25. https://doi.org/10.1161/CIRCULATIONAHA.108.829838
Rosenstein RS, Parra D. Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38". Circulation. 2009 Jun 30;119(25). https://doi.org/10.1161/CIRCULATIONAHA.108.829838
Rosenstein, Robert S. ; Parra, David. / Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel : Thrombolysis in myocardial infarction 38". In: Circulation. 2009 ; Vol. 119, No. 25.
@article{baba678796a546b3a9f957d0900f8c63,
title = "Letter by rosenstein and parra regarding article, {"}greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38{"}",
author = "Rosenstein, {Robert S.} and David Parra",
year = "2009",
month = "6",
day = "30",
doi = "10.1161/CIRCULATIONAHA.108.829838",
language = "English",
volume = "119",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel

T2 - Thrombolysis in myocardial infarction 38"

AU - Rosenstein, Robert S.

AU - Parra, David

PY - 2009/6/30

Y1 - 2009/6/30

UR - http://www.scopus.com/inward/record.url?scp=67650727967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650727967&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.829838

DO - 10.1161/CIRCULATIONAHA.108.829838

M3 - Article

C2 - 19564566

AN - SCOPUS:67650727967

VL - 119

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -

Access to Document